Almu’aTasim Khamees
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Almu’aTasim Khamees has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Khayry Al-Shami
Yarmouk University
12 shared publications - Khaled Seetan
Yarmouk University
9 shared publications - Raghad Yousef Yassin
Faculty of Pharmacy, Yarmouk University, Irbid, Jordan
8 shared publications - Saleh A. Ba-Shammakh
Princess Basma Teaching Hospital, Ministry of Health, Irbid, Jordan
8 shared publications Francesk Mulita
General University Hospital of Patras, Patras, Greece
7 shared publications- Mazhar Salim Al Zoubi
Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid 21163, Jordan
7 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (10)
Sex‐Specific Differences in Symptomatology and Quality of Life Impact of Allergic Rhinitis: A Cross‐Sectional Study
Background: Allergic Rhinitis (AR) is a widespread condition that significantly affects the quality of life (QOL) of those affected globally. It contributes to sleep disturbances, fatigue, poor concentration, irritability, and can worsen symptoms in individuals with coexisting asthma. This study examines the impact of AR on QOL in adults, with specific attention to sex differences. Materials and Methods: A cross‐sectional online survey using a purpose‐designed, non‐validated questionnaire was distributed via social media using convenience sampling to 1572 Jordanian adults. The questionnaire collected data on demographics, AR symptoms, triggers, and the impact of AR on mental health, social functioning, and daily life. Data were analyzed using descriptive statistics and Chi‐square tests. Multivariable logistic regression was used to adjust for potential confounders, and Benjamini–Hochberg false discovery rate (FDR) correction was applied to account for multiplicity. Results: A total of 1572 respondents participated; 683 (43.4%) had physician‐diagnosed AR. AR was reported by 157/419 males (37.5%) and 526/1153 females (45.6%); this sex difference was statistically significant ( χ 2 = 8.31, p = 0.004; OR = 1.40, 95% CI 1.11–1.76). Most patients lived in urban areas (69.4%). While sneezing and rhinorrhoea were common across sexes, females reported significantly higher rates of nasal itching/congestion (55.5% vs. 43.9%, p = 0.011), headaches (61.0% vs. 43.9%, p < 0.001), and increased stress/anxiety (53.4% vs. 42.7%, p = 0.018, not surviving false discovery rate (FDR) correction). In contrast, snoring was more prevalent in males (40.1% vs. 24.1%, p < 0.001). Regarding QOL, AR severely disrupted sleep (80.7%) and concentration (66.2%) for both sexes. However, females were significantly more likely to report irritability/emotional distress (65.4% vs. 55.4%, p = 0.023), prefer social isolation during symptoms (59.3% vs. 47.8%, p = 0.010), and experience limitations in activities outside the home (55.1% vs. 45.9%, p = 0.041). After adjustment, female sex remained significantly associated with irritability/emotional distress (aOR = 1.50, 95% CI 1.02–2.22, p = 0.039) and preference for social isolation (aOR = 1.53, 95% CI 1.05–2.23, p = 0.028). After Benjamini–Hochberg FDR correction, nasal itching/congestion, snoring, and headache remained statistically significant in symptom analyses; no QOL items survived FDR correction, and these findings should be considered exploratory. Asthma was reported by 80/683 (11.7%) of AR patients, more frequently among males than females (19.7% vs. 9.3%, p < 0.001). Sensitivity analyses showed that the association between female sex and social isolation was robust to adjustment for or exclusion of asthma, whereas the association with irritability was attenuated after excluding participants with asthma. Conclusion: These findings suggest AR's substantial impact on daily functioning and mental well‐being, with signals of greater psychosocial burden among women. Improved understanding of sex‐specific challenges can support more effective prevention, diagnosis, and management strategies, with tailored strategies to address the distinct symptom burden and QOL impairments experienced by female patients. These findings may provide preliminary insights into the burden of AR in Jordan and should be confirmed in representative, validated surveys.
- 22 October 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (10)
Open AccessSex‐Specific Differences in Symptomatology and Quality of Life Impact of Allergic Rhinitis: A Cross‐Sectional Study
Background: Allergic Rhinitis (AR) is a widespread condition that significantly affects the quality of life (QOL) of those affected globally. It contributes to sleep disturbances, fatigue, poor concentration, irritability, and can worsen symptoms in individuals with coexisting asthma. This study examines the impact of AR on QOL in adults, with specific attention to sex differences. Materials and Methods: A cross‐sectional online survey using a purpose‐designed, non‐validated questionnaire was distributed via social media using convenience sampling to 1572 Jordanian adults. The questionnaire collected data on demographics, AR symptoms, triggers, and the impact of AR on mental health, social functioning, and daily life. Data were analyzed using descriptive statistics and Chi‐square tests. Multivariable logistic regression was used to adjust for potential confounders, and Benjamini–Hochberg false discovery rate (FDR) correction was applied to account for multiplicity. Results: A total of 1572 respondents participated; 683 (43.4%) had physician‐diagnosed AR. AR was reported by 157/419 males (37.5%) and 526/1153 females (45.6%); this sex difference was statistically significant ( χ 2 = 8.31, p = 0.004; OR = 1.40, 95% CI 1.11–1.76). Most patients lived in urban areas (69.4%). While sneezing and rhinorrhoea were common across sexes, females reported significantly higher rates of nasal itching/congestion (55.5% vs. 43.9%, p = 0.011), headaches (61.0% vs. 43.9%, p < 0.001), and increased stress/anxiety (53.4% vs. 42.7%, p = 0.018, not surviving false discovery rate (FDR) correction). In contrast, snoring was more prevalent in males (40.1% vs. 24.1%, p < 0.001). Regarding QOL, AR severely disrupted sleep (80.7%) and concentration (66.2%) for both sexes. However, females were significantly more likely to report irritability/emotional distress (65.4% vs. 55.4%, p = 0.023), prefer social isolation during symptoms (59.3% vs. 47.8%, p = 0.010), and experience limitations in activities outside the home (55.1% vs. 45.9%, p = 0.041). After adjustment, female sex remained significantly associated with irritability/emotional distress (aOR = 1.50, 95% CI 1.02–2.22, p = 0.039) and preference for social isolation (aOR = 1.53, 95% CI 1.05–2.23, p = 0.028). After Benjamini–Hochberg FDR correction, nasal itching/congestion, snoring, and headache remained statistically significant in symptom analyses; no QOL items survived FDR correction, and these findings should be considered exploratory. Asthma was reported by 80/683 (11.7%) of AR patients, more frequently among males than females (19.7% vs. 9.3%, p < 0.001). Sensitivity analyses showed that the association between female sex and social isolation was robust to adjustment for or exclusion of asthma, whereas the association with irritability was attenuated after excluding participants with asthma. Conclusion: These findings suggest AR's substantial impact on daily functioning and mental well‐being, with signals of greater psychosocial burden among women. Improved understanding of sex‐specific challenges can support more effective prevention, diagnosis, and management strategies, with tailored strategies to address the distinct symptom burden and QOL impairments experienced by female patients. These findings may provide preliminary insights into the burden of AR in Jordan and should be confirmed in representative, validated surveys.
- Open Access
Self-Reported Changes in Sleep, Electronic Device Use, and Health-Application Uptake During the COVID-19 Lockdown: A Cross-Sectional Survey of Jordanian Internet Users
Background: The COVID-19 pandemic and related lockdowns have profoundly affected daily routines and lifestyle behaviors globally. Aims: This cross-sectional study is aimed at documenting the changes in sleep patterns, electronic device use, and health-application adoption during the lockdown period (COVID-19) among 2511 Jordanian internet users participating in an online convenience sample. Methods: An online survey was used to gather data on demographics, sleep habits, physical activity, diet, and digital health tool usage. Results: Among the surveyed participants, 39.9% reported increased sleep duration, 13.5% reported decreased sleep duration, and 46.6% reported no change. In multivariable logistic regression, participants aged 18–35 years (aOR = 1.95, 95% CI 1.28–2.99), single status (aOR = 1.77, 95% CI 1.39–2.26), health-related education (aOR = 1.38, 95% CI 1.01–1.88), and non-health or unemployed occupational status (aOR = 1.62 and 1.67, respectively) were independently associated with increased sleep duration. Increased electronic device use was independently associated with single status (aOR = 1.39, 95% CI 1.00–1.92) and higher educational attainment (aOR range 1.60–1.97). Among the 2138 participants who reported increased electronic device use, 70.7% reported online studying, and 67.8% reported leisure/spare time as reasons for the increase. Participants used nutrition, physical activity, and medical applications at 28.6%, 36.9%, and 35.2%, respectively. In adjusted models, female gender was independently associated with use of nutrition (aOR = 1.69, 95% CI 1.34–2.13), physical activity (aOR = 1.32, 95% CI 1.07–1.62), and medical applications (aOR = 1.41, 95% CI 1.14–1.73). Bivariate analyses were exploratory and used Monte Carlo exact tests where cell counts were sparse; individual nominal p-values should not be interpreted as confirmatory. Conclusions: These findings show substantial changes in sleep, electronic device use, and health-application uptake during the COVID-19 lockdown. This suggests that digital health interventions may be worth evaluating for promoting healthy behaviors during periods of restricted mobility. Because of the non-probability sampling strategy, retrospective self-report, and cross-sectional design, the findings should not be interpreted as evidence of causal effects. Further representative and longitudinal studies are warranted.
Open AccessSelf-Reported Changes in Sleep, Electronic Device Use, and Health-Application Uptake During the COVID-19 Lockdown: A Cross-Sectional Survey of Jordanian Internet Users
Background: The COVID-19 pandemic and related lockdowns have profoundly affected daily routines and lifestyle behaviors globally. Aims: This cross-sectional study is aimed at documenting the changes in sleep patterns, electronic device use, and health-application adoption during the lockdown period (COVID-19) among 2511 Jordanian internet users participating in an online convenience sample. Methods: An online survey was used to gather data on demographics, sleep habits, physical activity, diet, and digital health tool usage. Results: Among the surveyed participants, 39.9% reported increased sleep duration, 13.5% reported decreased sleep duration, and 46.6% reported no change. In multivariable logistic regression, participants aged 18–35 years (aOR = 1.95, 95% CI 1.28–2.99), single status (aOR = 1.77, 95% CI 1.39–2.26), health-related education (aOR = 1.38, 95% CI 1.01–1.88), and non-health or unemployed occupational status (aOR = 1.62 and 1.67, respectively) were independently associated with increased sleep duration. Increased electronic device use was independently associated with single status (aOR = 1.39, 95% CI 1.00–1.92) and higher educational attainment (aOR range 1.60–1.97). Among the 2138 participants who reported increased electronic device use, 70.7% reported online studying, and 67.8% reported leisure/spare time as reasons for the increase. Participants used nutrition, physical activity, and medical applications at 28.6%, 36.9%, and 35.2%, respectively. In adjusted models, female gender was independently associated with use of nutrition (aOR = 1.69, 95% CI 1.34–2.13), physical activity (aOR = 1.32, 95% CI 1.07–1.62), and medical applications (aOR = 1.41, 95% CI 1.14–1.73). Bivariate analyses were exploratory and used Monte Carlo exact tests where cell counts were sparse; individual nominal p-values should not be interpreted as confirmatory. Conclusions: These findings show substantial changes in sleep, electronic device use, and health-application uptake during the COVID-19 lockdown. This suggests that digital health interventions may be worth evaluating for promoting healthy behaviors during periods of restricted mobility. Because of the non-probability sampling strategy, retrospective self-report, and cross-sectional design, the findings should not be interpreted as evidence of causal effects. Further representative and longitudinal studies are warranted.
- 10 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 2886-2896
Thirty‐Day Mortality and Morbidity Outcomes in Abdominal Wall Necrotizing Soft Tissue Infections: The STANMORE Study
Background: Necrotizing soft tissue infection is a rapidly progressive soft tissue infection with a high mortality rate. Limited contemporary data exist on abdominal wall necrotizing soft tissue infections. This study aimed to assess 30‐day mortality and morbidity and identify associated clinical factors. Methods: This was a prospective, multinational, multicenter audit of adult patients (≥ 18 years) with abdominal wall necrotizing soft tissue infection presenting between January 1 and June 30, 2022. Data on demographics, comorbidities, clinical features, treatment, and outcomes were collected. Univariate and multivariate regression analysis were performed to identify independent risk factors for morbidity and mortality. Results: A total of 331 patients were included from 63 centers in 27 countries. Thirty‐day morbidity and mortality occurred in 200 patients (60.4%), with 47 deaths (14.2%). A LRINEC score ≥ 6 was observed in 134 out of 263 (51.0%) of cases. Common presenting signs were skin changes in 287 out of 327 cases (87.8%), pain out of proportion to clinical findings in 236 out of 311 cases (75.9%), and gas in soft tissue on imaging 210 out of 329 cases (63.8%). The median time to first antibiotics was 2 hours (Range 0–240 hours). The median time to surgery was 6 hours (Range 1–384 hours). In the mortality group, 29 out of 47 (61.7%) had diabetes, 33 out of 47 (70.2%) had hypertension, and 25 out of 47 (53.2%) had obesity. Bowel resection (38.3%, 18 out of 47), stoma formation (44.7%, 21 out of 47) and ICU admission (89.4%, 42 out of 47) were more common in the mortality group ( p < 0.05, OR 7.47). On multivariable analysis, polymicrobial infection (OR 1.73 CI 1.01–2.95) and bowel resection (OR 3.10 CI 1.22–7.88) were independently associated with morbidity, while increasing age (OR 1.04 CI 1.01–1.07), elevated creatinine (OR1 CI 1.00–1.01), bowel resection (OR 7.47 CI 2.99–18.62), and longer time to antibiotics (OR 1.02, CI 1.00–1.04) were independently associated with mortality ( p < 0.05). Conclusion: Abdominal wall necrotizing soft tissue infection is associated with high early morbidity and mortality. Delays in recognition and treatment remain critical contributors. Risk stratification may assist early identification and management.
- 10 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 2886-2896
Thirty‐Day Mortality and Morbidity Outcomes in Abdominal Wall Necrotizing Soft Tissue Infections: The STANMORE Study
Background: Necrotizing soft tissue infection is a rapidly progressive soft tissue infection with a high mortality rate. Limited contemporary data exist on abdominal wall necrotizing soft tissue infections. This study aimed to assess 30‐day mortality and morbidity and identify associated clinical factors. Methods: This was a prospective, multinational, multicenter audit of adult patients (≥ 18 years) with abdominal wall necrotizing soft tissue infection presenting between January 1 and June 30, 2022. Data on demographics, comorbidities, clinical features, treatment, and outcomes were collected. Univariate and multivariate regression analysis were performed to identify independent risk factors for morbidity and mortality. Results: A total of 331 patients were included from 63 centers in 27 countries. Thirty‐day morbidity and mortality occurred in 200 patients (60.4%), with 47 deaths (14.2%). A LRINEC score ≥ 6 was observed in 134 out of 263 (51.0%) of cases. Common presenting signs were skin changes in 287 out of 327 cases (87.8%), pain out of proportion to clinical findings in 236 out of 311 cases (75.9%), and gas in soft tissue on imaging 210 out of 329 cases (63.8%). The median time to first antibiotics was 2 hours (Range 0–240 hours). The median time to surgery was 6 hours (Range 1–384 hours). In the mortality group, 29 out of 47 (61.7%) had diabetes, 33 out of 47 (70.2%) had hypertension, and 25 out of 47 (53.2%) had obesity. Bowel resection (38.3%, 18 out of 47), stoma formation (44.7%, 21 out of 47) and ICU admission (89.4%, 42 out of 47) were more common in the mortality group ( p < 0.05, OR 7.47). On multivariable analysis, polymicrobial infection (OR 1.73 CI 1.01–2.95) and bowel resection (OR 3.10 CI 1.22–7.88) were independently associated with morbidity, while increasing age (OR 1.04 CI 1.01–1.07), elevated creatinine (OR1 CI 1.00–1.01), bowel resection (OR 7.47 CI 2.99–18.62), and longer time to antibiotics (OR 1.02, CI 1.00–1.04) were independently associated with mortality ( p < 0.05). Conclusion: Abdominal wall necrotizing soft tissue infection is associated with high early morbidity and mortality. Delays in recognition and treatment remain critical contributors. Risk stratification may assist early identification and management.
- 14 July 2026
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 46 (9) , 965-984
JAK Inhibitors in Inflammatory Skin Diseases: A 15,427-Patient Systematic Review and Meta-analysis of Clinical Trial and Real-World Outcomes
Background Janus kinase (JAK) inhibitors are a new class of medications that are changing how we treat inflammatory skin diseases. Even though these drugs are increasingly being approved for various skin conditions, there is still limited detailed comparison of their effectiveness, safety, and long-term effects across different diseases. Objective In this study, we systematically evaluated the use of JAK inhibitors in atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hidradenitis suppurativa across both trial and real-world settings. Methods We conducted a systematic review following PRISMA 2020 guidelines and searched major databases for randomized controlled trials (RCTs), open-label extensions, and real-world cohort studies published through May 2025. The main effectiveness outcomes included disease-specific measures: Eczema Area and Severity Index (EASI) for atopic dermatitis, Psoriasis Area and Severity Index (PASI) for psoriasis, Severity of Alopecia Tool (SALT) for alopecia areata, Vitiligo Area Scoring Index (VASI) for vitiligo, and Hidradenitis Suppurativa Clinical Response (HiSCR) for hidradenitis suppurativa. Safety outcomes included rates of adverse events, infections, thromboembolism, and cancer. Patient-centered outcomes included quality of life (DLQI) and pruritus reduction. Risk of bias was assessed using the Cochrane Risk of Bias tool 2.0 (RoB 2). Results We included 68 studies (42 RCTs, 14 open-label extensions, and 12 real-world cohorts) with 15,427 patients across five inflammatory skin diseases. Oral JAK inhibitors demonstrated efficacy across multiple conditions compared with placebo, with EASI-75 response rates ranging from 38 to 73% in atopic dermatitis, PASI-75 rates ranging from 33 to 67% in psoriasis, and SALT-50 rates from 30 to 62% in alopecia areata. Topical JAK inhibitors have proven effective for atopic dermatitis and vitiligo but have shown limited benefit in alopecia areata. Safety profiles were generally similar across drugs, with higher rates of upper respiratory infections (5–14%) and herpes zoster reactivation (1–3%) compared with placebo. Serious adverse events, such as major cardiovascular events, venous thromboembolism, and cancers, were rare but did occur. Conclusions JAK inhibitors demonstrate significant efficacy across several inflammatory skin diseases, with a safety profile that warrants ongoing monitoring, particularly in patients with cardiovascular risk factors. Comparative data suggest that selective JAK1 inhibitors appear to offer the most favorable balance between efficacy and safety for atopic dermatitis, whereas JAK1/2 inhibitors showed numerically higher efficacy for alopecia areata, though this difference did not reach statistical significance. However, the interpretation of long-term safety and comparative effectiveness is constrained by the limited duration of controlled trials, under-representation of diverse populations, and reliance on indirect comparisons. PROSPERO registration: CRD420251045477.
- 14 July 2026
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 46 (9) , 965-984
JAK Inhibitors in Inflammatory Skin Diseases: A 15,427-Patient Systematic Review and Meta-analysis of Clinical Trial and Real-World Outcomes
Background Janus kinase (JAK) inhibitors are a new class of medications that are changing how we treat inflammatory skin diseases. Even though these drugs are increasingly being approved for various skin conditions, there is still limited detailed comparison of their effectiveness, safety, and long-term effects across different diseases. Objective In this study, we systematically evaluated the use of JAK inhibitors in atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hidradenitis suppurativa across both trial and real-world settings. Methods We conducted a systematic review following PRISMA 2020 guidelines and searched major databases for randomized controlled trials (RCTs), open-label extensions, and real-world cohort studies published through May 2025. The main effectiveness outcomes included disease-specific measures: Eczema Area and Severity Index (EASI) for atopic dermatitis, Psoriasis Area and Severity Index (PASI) for psoriasis, Severity of Alopecia Tool (SALT) for alopecia areata, Vitiligo Area Scoring Index (VASI) for vitiligo, and Hidradenitis Suppurativa Clinical Response (HiSCR) for hidradenitis suppurativa. Safety outcomes included rates of adverse events, infections, thromboembolism, and cancer. Patient-centered outcomes included quality of life (DLQI) and pruritus reduction. Risk of bias was assessed using the Cochrane Risk of Bias tool 2.0 (RoB 2). Results We included 68 studies (42 RCTs, 14 open-label extensions, and 12 real-world cohorts) with 15,427 patients across five inflammatory skin diseases. Oral JAK inhibitors demonstrated efficacy across multiple conditions compared with placebo, with EASI-75 response rates ranging from 38 to 73% in atopic dermatitis, PASI-75 rates ranging from 33 to 67% in psoriasis, and SALT-50 rates from 30 to 62% in alopecia areata. Topical JAK inhibitors have proven effective for atopic dermatitis and vitiligo but have shown limited benefit in alopecia areata. Safety profiles were generally similar across drugs, with higher rates of upper respiratory infections (5–14%) and herpes zoster reactivation (1–3%) compared with placebo. Serious adverse events, such as major cardiovascular events, venous thromboembolism, and cancers, were rare but did occur. Conclusions JAK inhibitors demonstrate significant efficacy across several inflammatory skin diseases, with a safety profile that warrants ongoing monitoring, particularly in patients with cardiovascular risk factors. Comparative data suggest that selective JAK1 inhibitors appear to offer the most favorable balance between efficacy and safety for atopic dermatitis, whereas JAK1/2 inhibitors showed numerically higher efficacy for alopecia areata, though this difference did not reach statistical significance. However, the interpretation of long-term safety and comparative effectiveness is constrained by the limited duration of controlled trials, under-representation of diverse populations, and reliance on indirect comparisons. PROSPERO registration: CRD420251045477.
- 6 July 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (8) , 4497-4499
Correction to: Global 30-Day Morbidity and Mortality of Primary Bariatric Surgery Combined with Another Procedure: The BLEND Study
- 6 July 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (8) , 4497-4499
Correction to: Global 30-Day Morbidity and Mortality of Primary Bariatric Surgery Combined with Another Procedure: The BLEND Study
- 2 July 2026
- Published by Springer Nature
- p. 557-578
Urology: Special Instruments
- 2 July 2026
- Published by Springer Nature
- p. 47-58
C-Arm Fluoroscope
- Open Access
Preoperative Risk Evaluation for Cancer Treatment (PREdiCT): protocol for an international cohort study evaluating a trimodal screening tool to predict outcomes following gastrointestinal cancer surgery
Introduction: Gastrointestinal cancer surgery commonly leads to postoperative complications and other adverse outcomes. While prehabilitation shows promise in reducing adverse postoperative outcomes, most hospitals have resource limitations that preclude its use as standard of care. Additionally, the need to expedite surgery from diagnosis often creates a narrow window for prehabilitation initiatives. Online, self-reported screening tools may address these challenges by facilitating early identification of high-risk patients and enabling targeted preoperative interventions, thereby allowing equitable allocation of limited resources. Therefore, the primary aim of this study is to evaluate the predictive utility of a tri-modal (physical, nutritional, psychological) screening tool for patients undergoing gastrointestinal cancer surgery. Methods: This prospective international cohort study will recruit 1214 adults undergoing elective gastrointestinal cancer surgery across 35 sites from 19 countries. Participants will complete an online screening tool developed through a comprehensive, multistep, predefined process. The screening tool comprises the Duke Activity Status Index, Patient-Generated Subjective Global Assessment Short Form and the Patient Health Questionnaire-4, in English, Spanish, French or Portuguese. These tools were selected based on a scoping review, followed by an international Delphi consensus process. The primary outcomes include rate of postoperative complications, major complications (Clavien-Dindo Classification grade III–V) and overall complication severity assessed by the Comprehensive Complications Index; all assessed 30 days postoperatively. Secondary outcomes include hospital length of stay, readmission rate within 30 days, discharge destination (home vs other), days at home and alive in 30 days postsurgery, 30-day all-cause mortality and 12-month survival. Primary analyses will establish optimal screening tool cut-points to stratify patients into clinically actionable risk categories for postoperative complications and examine the independent predictive value of these screening scores after adjusting for established clinical risk factors. Ethics and dissemination: This study has received ethical approval from the Sydney Local Health District Human Research and Ethics Committee (X25-0333 and 2025/ETH02465) and has been registered on the Open Science Framework (10.17605/OSF.IO/HVCGD). The results of Preoperative Risk Evaluation for Cancer Treatment will be submitted to reputable journals and presented at national and international conferences.
Open AccessPreoperative Risk Evaluation for Cancer Treatment (PREdiCT): protocol for an international cohort study evaluating a trimodal screening tool to predict outcomes following gastrointestinal cancer surgery
Introduction: Gastrointestinal cancer surgery commonly leads to postoperative complications and other adverse outcomes. While prehabilitation shows promise in reducing adverse postoperative outcomes, most hospitals have resource limitations that preclude its use as standard of care. Additionally, the need to expedite surgery from diagnosis often creates a narrow window for prehabilitation initiatives. Online, self-reported screening tools may address these challenges by facilitating early identification of high-risk patients and enabling targeted preoperative interventions, thereby allowing equitable allocation of limited resources. Therefore, the primary aim of this study is to evaluate the predictive utility of a tri-modal (physical, nutritional, psychological) screening tool for patients undergoing gastrointestinal cancer surgery. Methods: This prospective international cohort study will recruit 1214 adults undergoing elective gastrointestinal cancer surgery across 35 sites from 19 countries. Participants will complete an online screening tool developed through a comprehensive, multistep, predefined process. The screening tool comprises the Duke Activity Status Index, Patient-Generated Subjective Global Assessment Short Form and the Patient Health Questionnaire-4, in English, Spanish, French or Portuguese. These tools were selected based on a scoping review, followed by an international Delphi consensus process. The primary outcomes include rate of postoperative complications, major complications (Clavien-Dindo Classification grade III–V) and overall complication severity assessed by the Comprehensive Complications Index; all assessed 30 days postoperatively. Secondary outcomes include hospital length of stay, readmission rate within 30 days, discharge destination (home vs other), days at home and alive in 30 days postsurgery, 30-day all-cause mortality and 12-month survival. Primary analyses will establish optimal screening tool cut-points to stratify patients into clinically actionable risk categories for postoperative complications and examine the independent predictive value of these screening scores after adjusting for established clinical risk factors. Ethics and dissemination: This study has received ethical approval from the Sydney Local Health District Human Research and Ethics Committee (X25-0333 and 2025/ETH02465) and has been registered on the Open Science Framework (10.17605/OSF.IO/HVCGD). The results of Preoperative Risk Evaluation for Cancer Treatment will be submitted to reputable journals and presented at national and international conferences.
- Open Access
- 15 June 2026
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 18 (14) , 1907-1923
Urease inhibitors: current advances, therapeutic potentials, and clinical challenges
Urease is a nickel-dependent metalloenzyme that catalyzes urea hydrolysis, generating ammonia and elevating local pH, a process implicated in the pathogenesis of Helicobacter pylori-associated peptic ulcer disease (PUD). To identify effective urease inhibitors, acetohydroxamic acid (AHA) remains the only FDA-approved agent, with clinical use constrained by toxicity. This review synthesizes current evidence on urease inhibition strategies, encompassing metal-based complexes, organic derivatives, natural products, peptide inhibitors, nanotechnology-enabled systems, and emerging gene-based approaches. Several candidates, including copper-based compounds and the natural alkaloid palmatine (PAL), demonstrate potent urease inhibition and favorable effects in preclinical models. However, translation to clinical practice is limited by safety concerns, instability, and a paucity of human trials. Advancing hybrid molecules, optimized delivery platforms, and combination therapies may enhance therapeutic efficacy. Rigorous clinical evaluation remains essential to establish urease inhibition as a viable strategy in urease-mediated diseases.
- 15 June 2026
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 18 (14) , 1907-1923
Open AccessUrease inhibitors: current advances, therapeutic potentials, and clinical challenges
Urease is a nickel-dependent metalloenzyme that catalyzes urea hydrolysis, generating ammonia and elevating local pH, a process implicated in the pathogenesis of Helicobacter pylori-associated peptic ulcer disease (PUD). To identify effective urease inhibitors, acetohydroxamic acid (AHA) remains the only FDA-approved agent, with clinical use constrained by toxicity. This review synthesizes current evidence on urease inhibition strategies, encompassing metal-based complexes, organic derivatives, natural products, peptide inhibitors, nanotechnology-enabled systems, and emerging gene-based approaches. Several candidates, including copper-based compounds and the natural alkaloid palmatine (PAL), demonstrate potent urease inhibition and favorable effects in preclinical models. However, translation to clinical practice is limited by safety concerns, instability, and a paucity of human trials. Advancing hybrid molecules, optimized delivery platforms, and combination therapies may enhance therapeutic efficacy. Rigorous clinical evaluation remains essential to establish urease inhibition as a viable strategy in urease-mediated diseases.